Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd is an Australia-based clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for cancer. Its pipeline spans peptides, small molecules, and monoclonal antibodies designed to target solid tumors across multiple indications.
Business
Share of revenueCancer-targeted radioactive drug candidates intended to treat tumors.
Radiolabeled agents used to visualize and characterize tumors.
Peptide-based assets used in targeted oncology imaging and therapy.
Small-molecule radiopharmaceutical candidates such as RAD 101.
Antibody-based radiopharmaceutical assets for targeted cancer applications.
Customers
Radiopharm’s customers are primarily oncology researchers, clinical trial sites, and eventual hospital and specialist physician users of approved diagnostic or therapeutic agents. In the current development stage, value is created through clinical data generation, trial enrollment, and partnering rather than broad commercial sales. The relevant end markets are patients with solid tumors, especially in lung, breast, prostate, and brain cancers.
Hospitals and research centers that enroll patients and generate data for the pipeline.
Specialist physicians and cancer centers that would use approved imaging or therapy products.
Biopharma partners that may license or co-develop radiopharmaceutical assets.
Patients in lung, breast, prostate, brain and other solid tumor indications targeted by the pipeline.
Strategy
Radiopharm’s strategy is to advance a differentiated pipeline of radiopharmaceutical assets through clinical milestones and expand the evidence base for partnering or later-stage development. A key priority is progressing multiple programs across peptides, small molecules, and antibodies so the company is not dependent on a single asset. The company also emphasizes strategic partnering and external funding to support development across its oncology pipeline.
Clinical data is the main value driver for a radiopharmaceutical developer.
Multiple modalities reduce single-asset dependence and improve partnering optionality.
Partnerships can fund development and validate asset quality.
Geography
The company is incorporated and headquartered in Australia, with principal offices in Carlton, Victoria, and it also has a U.S. market presence through NASDAQ listing and investor relations activity. Its clinical programs are global in scope, but the business is operationally centered in Australia and the United States. Geography matters because clinical development, capital access, and future commercialization will depend on regulatory and trial execution across multiple jurisdictions.
Risks
As a clinical-stage biopharma company, Radiopharm faces substantial execution risk because value depends on trial enrollment, clinical outcomes, and regulatory progress. It also relies on external financing and partner interest to fund ongoing development, which makes capital access and dilution important business risks. More broadly, radiopharmaceutical development carries scientific, manufacturing, and safety risks, particularly for novel oncology assets.
- Clinical development failureImpact: HighLikelihood: High
Pipeline value depends on positive data from Phase 1 and Phase 2 studies.
Exposure: RAD 101 and other oncology programs
- Funding and dilution riskImpact: HighLikelihood: High
The business is pre-commercial and needs external capital to finance trials.
Exposure: Working capital and development funding
- Regulatory and trial execution riskImpact: HighLikelihood: High
Approvals, site activation, and enrollment affect timing and outcomes.
Exposure: Global clinical programs
- Manufacturing and radioisotope complexityImpact: MediumLikelihood: Medium
Radiopharmaceutical products require specialized production, logistics, and safety controls.
Exposure: Clinical supply chain
Accounting
Judgemental itemsAny contract revenue must be recognized based on service delivery or contract terms.
Impact: Can make revenue uneven and hard to compare period to period
Clinical trial and preclinical spend is a core operating cost in this business model.
Impact: Drives reported losses and cash burn
The company disclosed a material uncertainty in relation to going concern.
Impact: Important for assessing financing risk and continuity
Clinical-stage assets and financing instruments may require valuation estimates.
Impact: Can materially affect reported assets and earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
Radnostix Inc
INIS · Industrial Instruments For Measurement, Display, and Control
RADNOSTIX INC is part of a U.S.-based nuclear medicine and isotope business that manufactures calibration and reference standards, radiochemical products, and cobalt-based source products.
Telix Pharmaceuticals Ltd
TLX · Pharmaceutical Preparations
Telix Pharmaceuticals Ltd is an Australia-headquartered biopharmaceutical company that develops and commercializes radiopharmaceuticals for oncology and rare disease applications.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
RadNet, Inc.
RDNT · Services-Medical Laboratories
Agentix Corp.
AGTX · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026